Scarica l'app Stockscreener
18.73
1.22%
-0.24
Dopo l'orario di chiusura:
19.06
0.33
+1.76%
Precedente Chiudi:
$18.97
Aprire:
$19.24
Volume 24 ore:
406.42K
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.18B
Reddito:
$10.00M
Utile/perdita netta:
$-377.74M
Rapporto P/E:
-2.2182
EPS:
-8.4436
Flusso di cassa netto:
$-172.35M
1 W Prestazione:
+5.04%
1M Prestazione:
+3.02%
6M Prestazione:
-53.77%
1 anno Prestazione:
+63.94%
Intervallo 1D:
$18.61
$19.27
Intervallo di 1 settimana:
$17.85
$20.19
Portata 52W:
$8.91
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
18.73 | 1.20B | 10.00M | -377.74M | -172.35M | -8.4436 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders - Sahm
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
Zenas BioPharma to present obexelimab trial data at EULAR congress - Investing.com UK
Zenas BioPharma to present obexelimab trial data at EULAR congress By Investing.com - Investing.com Nigeria
Why is Zenas Biopharma stock climbing today? By Investing.com - Investing.com Australia
Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target - RTTNews
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - The Manila Times
Obexelimab cuts IgG4-RD flare risk 56%, results to be presented at EULAR 2026 - Stock Titan
Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing - Moomoo
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock - Investing.com Australia
Zenas BioPharma (ZBIO) CEO adds 60,000 shares in open-market buy - Stock Titan
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment - TipRanks
New hires at Zenas BioPharma get 51,075 stock units over 4 years - Stock Titan
Zenas BioPharma rises as CEO continues insider purchases - MSN
Assessing Zenas BioPharma (ZBIO) Valuation After Obexelimab Phase 3 Success And New IL-17 Program Progress - Sahm
Vanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIO - MarketBeat
ZBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $22 - Moomoo
How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors - Sahm
ZBIO SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Zenas BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - Yahoo Finance
Zenas BioPharma 4Q Loss/Shr $1.46 >ZBIO - Moomoo
Zenas BioPharma, Inc. 2026 Q1 Financial Report: Forward-Looking Statements, Risk Factors, and Management Discussion - Minichart
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021 - TipRanks
Zenas BioPharma doses first patient in ZB021 phase 1 trial By Investing.com - Investing.com Nigeria
Zenas BioPharma doses first patient in ZB021 phase 1 trial - Investing.com
Zenas BioPharma Reports Q1 2026 Results: Obexelimab Nears FDA Submission for IgG4-RD, Pipeline Advances, and Cash Runway Extended to 2029 1245 - Minichart
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - The Manila Times
Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor - TradingView
Zenas BioPharma (Nasdaq: ZBIO) doubles cash while quarterly loss widens - Stock Titan
Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year - TipRanks
Zenas BioPharma Highlights Strong Q1 Progress and Financing - TipRanks
Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary - TradingView
Zenas BioPharma (NASDAQ: ZBIO) widens loss but lifts cash to $718.5M - Stock Titan
Tomas Kiselak resigns from Zenas BioPharma board after term expiration - TradingView
Zenas BioPharma Q1 Net Loss Widens - Moomoo
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss - marketscreener.com
Zenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory Submissions - Quiver Quantitative
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, Vs. FactSet Est of $1.47 Loss - Moomoo
TradingKey - TradingKey
Number of shareholders of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Zenas BioPharma (ZBIO) CEO and entities report 3,220,880 shares owned - Stock Titan
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zenas Biopharma Inc Azioni (ZBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Apr 29 '26 |
Buy |
17.62 |
35,000 |
616,700 |
1,786,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):